The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 20, 2017
Filed:
Dec. 09, 2015
Frederic Zecri, Brookline, MA (US);
Philipp Grosche, Inzlingen, DE;
Kayo Yasoshima, Cambridge, MA (US);
Hongjuan Zhao, Lexington, MA (US);
Jun Yuan, Boston, MA (US);
Aimee Richardson Usera, Winchester, MA (US);
Changgang Lou, Somervilee, MA (US);
Aaron Kanter, Somerville, MA (US);
Alexandra Marshall Bruce, Cambridge, MA (US);
Carla Guimaraes, Boston, MA (US);
Frederic Zecri, Brookline, MA (US);
Philipp Grosche, Inzlingen, DE;
Kayo Yasoshima, Cambridge, MA (US);
Hongjuan Zhao, Lexington, MA (US);
Jun Yuan, Boston, MA (US);
Aimee Richardson Usera, Winchester, MA (US);
Changgang Lou, Somervilee, MA (US);
Aaron Kanter, Somerville, MA (US);
Alexandra Marshall Bruce, Cambridge, MA (US);
Carla Guimaraes, Boston, MA (US);
NOVARTIS AG, Basel, CH;
Abstract
The invention provides a cyclic polypeptide of Formula I (SEQ ID NO: 1):X1-R-X3-X4-L-S-X7-X8-X9-X10-X11-X12-X13  I or an amide, an ester or a salt thereof, or a bioconjugate thereof, wherein X1, X3, X4, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention or bioconjugates thereof, and their therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.